Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PSORIASIS Clear all

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn's Disease
Interventions: Infliximab; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 12 Years and older
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Plaque Psoriasis
Interventions: 188-0551 Solution, Vehicle Solution; Drug
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Arlington Heights, Illinois

Conditions: Nail Psoriasis
Interventions: 308 nm excimer laser, Sham laser; Device
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Psoriasis
Interventions: Injections of tildrakizumab; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: San Diego, California • Grandville, Michigan

Conditions: Plaque Psoriasis
Interventions: Autonomic Nerve Modulation - Active, Autonomic Nerve Modulation - Control; Device
Lead sponsor: Thync Global, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Fremont, California

Conditions: Plaque Psoriasis
Interventions: ME3183, Placebo; Drug
Lead sponsor: Meiji Pharma USA Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 14
States / cities: Rogers, Arkansas • Los Angeles, California • Denver, Colorado + 11 more

Conditions: Pruritus, Psoriasis Vulgaris
Interventions: SNA-120, Vehicle; Drug
Lead sponsor: Sienna Biopharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 38
States / cities: Scottsdale, Arizona • Fort Smith, Arkansas • Fountain Valley, California + 35 more

Conditions: Moderate to Severe Psoriatic Arthritis
Interventions: DDY391, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Huntington Beach, California • Duncansville, Pennsylvania • Philadelphia, Pennsylvania + 5 more

Conditions: Psoriasis
Interventions: 80 mg ixekizumab Dosing Regimen, 50 mg etanercept, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 41
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 38 more

Conditions: Spondyloarthritis
Interventions: Not listed
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Plaque Psoriasis
Interventions: CHS-1420, Adalimumab; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 28
States / cities: Phoenix, Arizona • Encino, California • Sacramento, California + 23 more

Conditions: Arthritis, Psoriatic
Interventions: golimumab, Placebo; golimumab; Biological
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 18
States / cities: Huntsville, Alabama • La Jolla, California • Upland, California + 15 more

Conditions: Psoriasis
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Scalp Psoriasis
Interventions: Calcipotriene/Betamethasone Dipropionate, Taclonex®, Placebo; Drug
Lead sponsor: Glenmark Pharmaceuticals Ltd. India; Industry
Eligibility: 18 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 31
States / cities: Encinitas, California • Fremont, California • San Diego, California + 25 more

Conditions: Plaque Psoriasis
Interventions: Etanercept, CHS-0214; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 521 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 50
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 43 more

Conditions: Psoriasis
Interventions: M518101, Vehicle; Drug
Lead sponsor: Maruho North America Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Tustin, California

Conditions: Psoriasis, Psoriatic Arthritis
Interventions: Not listed
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: Not listed
Enrollment: 999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Psoriatic Arthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
Interventions: Ultrasound Stimulation, Non-active ultrasound stimulation; Device
Lead sponsor: Surf Therapeutics; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Austin, Texas • Houston, Texas

Conditions: Plaque Psoriasis
Interventions: Secukinumab; Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Psoriatic Arthritis
Interventions: Placebo, Risankizumab; Biological
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 964 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 59
States / cities: Anniston, Alabama • Peoria, Arizona • Phoenix, Arizona + 53 more

Conditions: Psoriasis
Interventions: ARQ-151 cream 0.5%, ARQ-151 cream 0.15%, ARQ-151 vehicle cream; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Autoimmune Diseases, Rheumatoid Arthritis (RA), Inflammatory Bowel Disease (IBD), Psoriasis (PsO)
Interventions: Offered an academic detailing session, Standard-of-care outreach from the insurance plan; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: Not listed
Enrollment: 1,325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Louisville, Kentucky • Boston, Massachusetts

Conditions: Psoriatic Arthritis
Interventions: Secukinumab, Adalimumab; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 853 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 19
States / cities: Fountain Valley, California • Fullerton, California • La Mesa, California + 16 more

Conditions: Psoriasis
Interventions: Calcipotriene Foam, Vehicle Foam; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 12 Years and older
Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 26
States / cities: Tucson, Arizona • San Diego, California • Denver, Colorado + 22 more

Search by objective public record fields.

Centocor Microarray Study of Patients

A Comparison of 188-0551 Solution Versus Vehicle Solution in Subjects With Plaque Psoriasis (Study 203)

308nm Excimer Laser for Treatment of Fingernail Psoriasis

A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis

Efficacy and Safety Study of Autonomic Nerve Modulation (ANM) in Subjects With Moderate Plaque Psoriasis

Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis

Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris

A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis

A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)

A Study of Novel Immune Modulating Biomarkers in Patients With Spondyloarthritis With Axial Involvement

Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis

A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis

Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis

Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)

Study to Evaluate the Pharmacokinetics and the Safety of M518101 in Plaque Psoriasis Patients

Study of Psoriatic Arthritis

Activating the Cholinergic Anti-Inflammatory Pathway in Healthy Volunteers and People With Inflammatory Arthritis

Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis

A Trial of Academic Detailing to Promote Prescribing of Biosimilars

Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis

The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis